News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Novartis AG’s Onbrez Better Than Pfizer Inc.'s Drug Spiriva In COPD
November 3, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Nov 3 (Reuters) - Swiss drugmaker Novartis AG's (NOVN.VX) lung drug Onbrez reduced breathlessness more effectively than Pfizer's (PFE.N) Spiriva in patients with a deadly lung disease, a late-stage trial found.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
Pfizer
Novartis
MORE ON THIS TOPIC
Policy
HHS To Require Placebo-Controlled Trials for All New Vaccines in ‘Radical Departure’ From Past
May 1, 2025
·
3 min read
·
Heather McKenzie
Multiple sclerosis
Immunic Talks Up Disability Gains as Phase II MS Therapy Fails on Primary Endpoint
May 1, 2025
·
2 min read
·
Tristan Manalac
Cancer
AACR 2025 Tracker: Merck, GSK, Roche and More Present Key Data
April 30, 2025
·
8 min read
·
BioSpace Editorial Staff
Prostate cancer
AstraZeneca’s Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
April 30, 2025
·
2 min read
·
Tristan Manalac